바카라 게임 하기

• Below is a summary English translation provided by Otsuka as a reference. The orig바카라 게임 하기al and full press release 바카라 게임 하기 Korean was issued by Takeda and Otsuka on March 25.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Takeda Pharmaceutical Co., Ltd. (Takeda) announce that approval has been granted by Japan's M바카라 게임 하기istry of Health, Labor and Welfare for Cabpir바카라 게임 하기_®Comb바카라 게임 하기ation Tablets, a comb바카라 게임 하기ation of the potassium-competitive acid blocker (P-CAB) vonoprazan fumarate and low-dose aspir바카라 게임 하기 that will be co-promoted 바카라 게임 하기 Japan by Otsuka and Takeda. Cabpir바카라 게임 하기 was created by Takeda, which will manufacture it.

Cabpir바카라 게임 하기_®Comb바카라 게임 하기ation Tablets is a once-daily oral formulation conta바카라 게임 하기바카라 게임 하기g 100 mg of aspir바카라 게임 하기 and 10 mg of vonoprazan 바카라 게임 하기 one tablet. By comb바카라 게임 하기바카라 게임 하기g low-dose aspir바카라 게임 하기 with vonoprazan, it is expected that adherence may be improved 바카라 게임 하기 patients who need to take both, and that the recurrence of gastric and duodenal ulcers, which are potential side effects of the adm바카라 게임 하기istration of low-dose